Biggest News Aggregation in the World
📰 Beigene News

Page 13 - Beigene News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Beigene. Real-time updates on events, politics, business and more.

BeiGene: BRUKINSA (zanubrutinib) Receives Marketing Authorization for Chronic Lymphocytic Leukemia (CLL) and Marginal Zone Lymphoma (MZL) in Great Britain by MHRA

MHRA marketing authorizations follow recent European Commission marketing authorizations BRUKINSA is the only treatment authorized for MZL in Great Britain BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE:
United States United Kingdom South Korea Northern Ireland Great Britain Mehrdad Mobasher

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

BeiGene's BRUKINSA (zanubrutinib) Demonstrated Superior Progression-Free Survival Over IMBRUVICA (ibrutinib) in Chronic Lymphocytic Leukemia in Late-Breaker at ASH

Final ALPINE Progression-Free Survival (PFS) results simultaneously published in The New England Journal of Medicine and presented at late-breaking session at 64th American Society of Hematology Annual
United States New Zealand United Kingdom South Korea Great Britain Mehrdad Mobasher

BeiGene Calls for Greater Integration of Mental Health in Cancer Care After New Survey Reveals Gaps/Barriers for Patients and Survivors

09.12.2022 - BeiGene, a global biotechnology company, is convening diverse stakeholders to amplify the mental health needs of the cancer community during an event hosted for patient advocates and scientists attending the American Society of Hematology (ASH) ... Seite 1
Cancer Support Community Significant Barriers To Mental Health Care Maia Thrift Perry Global Advocacy Director Cancer Experience Registry Prevalent Across

BeiGene to Present Final PFS Results from ALPINE Trial Demonstrating Superior PFS for BRUKINSA Versus IMBRUVICA in Late-Breaking Oral Session at ASH 2022

22.11.2022 - BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235) a global biotechnology company, today announced that the results of the final progression free survival (PFS) analysis of the ALPINE trial will be presented at a late-breaking oral presentation ... Seite 1
Mehrdad Mobasher Chief Medical Officer

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science